FOLLOWUS
Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus
- Chinese Journal of Integrative Medicine Vol. 20, Issue 1, Pages: 49-55(2014)
- Affiliations：
East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, Soul,Korea
- Author bio：
- Funds：These authors contributed equally to the manuscript
DOI：10.1007/s11655-012-1084-0
CLC：Published：2014，
Published Online：19 May 2012，
Scan for full text
Park, JW., Yoon, J., Cho, CK. et al. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus., Chin. J. Integr. Med. 20, 49–55 (2014). https://doi.org/10.1007/s11655-012-1084-0
Jae-Woo Park, Jeungwon Yoon, Chong-Kwan Cho, et al. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. [J]. Chinese Journal of Integrative Medicine 20(1):49-55(2014)
Park, JW., Yoon, J., Cho, CK. et al. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus., Chin. J. Integr. Med. 20, 49–55 (2014). https://doi.org/10.1007/s11655-012-1084-0 DOI：
Jae-Woo Park, Jeungwon Yoon, Chong-Kwan Cho, et al. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. [J]. Chinese Journal of Integrative Medicine 20(1):49-55(2014) DOI： 10.1007/s11655-012-1084-0.
摘要
To evaluate the efficacy of HangAm-Plus (HAP) on stage IV metastatic gastric cancer by analyzing the treated patients’ overall survival outcome. Following the study eligibility
overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only (n=18) and combined treatment of concurrent conventional chemotherapy and HAP (n=26). Patient characteristics by gender
age
surgical intervention
Eastern Cooperative Oncology Group (ECOG) score
treatment duration (< 4 weeks or ⩾4 weeks)
and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed. The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%
respectively (P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%
respectively (P=0.001). The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage IV metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.
Abstract
To evaluate the efficacy of HangAm-Plus (HAP) on stage IV metastatic gastric cancer by analyzing the treated patients’ overall survival outcome. Following the study eligibility
overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only (n=18) and combined treatment of concurrent conventional chemotherapy and HAP (n=26). Patient characteristics by gender
age
surgical intervention
Eastern Cooperative Oncology Group (ECOG) score
treatment duration (< 4 weeks or ⩾4 weeks)
and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed. The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%
respectively (P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%
respectively (P=0.001). The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage IV metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.
关键词
advanced gastric cancersupportive careChinese Materia MedicaOriental Medicine
Keywords
advanced gastric cancersupportive careChinese Materia MedicaOriental Medicine
references
Shin HR, Won YJ, Jung KW, Park JG. 2001 annual report of the Korea Central Cancer Registry: base on registered data from 134 hospitals. Cancer Res Treat 2004;36:19–30.
Cancer Facts and Figures 2010. Seoul, Korea: National Cancer Center, Ministry of Health & Welfare: 2010.
Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, et al. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and doceetaxel (FLOT), a translational study of the Arbetisgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2009;20:481–485.
Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207–2212
Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–591.
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.
Hijioka S, Chin K, Seto Y, Yamamoto N, Hatake K. Eightyear survival after advanced gastric cancer treated with S-1 followed by surgery. World J Gastroenterol 2010;16:2824–2827.
Tham CK, Choo SP, Poon DY, Toh HC, Ong SY, Tan SH, et al. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010;16:3709–3715.
Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009;20:475–480.
Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813–3818.
Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215–221.
Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008;38:176–181.
Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial. Jpn J Clin Oncol 2009;39:713–719.
Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, et al. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum and fluoropyrimidine-based regimens. J Oncol Pharm Pract 2010;16:173–178.
Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, et al. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: trial for advanced stromach cancer (TASC). Jpn J Clin Oncol 2007;37:469–472.
Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The effects of HangAmDan (HAD) on anti-metastasis and preventing relapses, administered to 69 cancer patients. Kor J Orient Int Med 2002;23:165–173.
Park JS, Yoo HS, Lee YW, Cho JH, Son CG, Cho CK. Wheel balance cancer therapy in the treatment of metastatic gastric carcinoma: a retrospective analysis of 62 patients. Kor J Orient Int Med 2007;28:531–543.
Choi BL, Kim HC, Song KC, Yoo HS, Cho JH, Lee YW, et al. Study on the toxicity of HangAm-Dan (HAD) in mice. J Kor Orient Oncol 2002;8:23–35.
Lee DE, Lee SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor effect of Hang-Am-Dan (HAD) and its ingredients on Calu6 and MCF-7 human cancer cell lines. J Kor Oriental Med 2009;30:50–60.
Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. Bio Chip J 2010;4:350–355.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Aug 9, 2006. Retrieved from: URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
Korea Central Cancer Registry, Ministry of Health and Welfare. 2009. Retrieved from: URL: http://www.cancer.go.kr/cms/statics/incidence/index.html
Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010;46:885–891.
Wagner AD, Grothe W, Haerting J, Kleber G. Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903–2909.
Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063–1069.
Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K, Ohdan H. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol 2010;8(40):1–7.
Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011;67:1435–1443
Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666–673.
Masashi F. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008;13:201–205.
Cunningham D, Straling N, Rao S, Iverson T, Nicloson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.
Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529–1534.
van Cutsem E, Moiseysnko VM, Tjulandin S, Majlis A, Constenal M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997.
Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148–157.
Kim BG, Oh SY, Kwon HC, Lee s, Lee DM, Kim SG, et al. A phase II study of irinotecan with biweekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Am J Clin Oncol 2010;33:246–250.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.
Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progressionfree survival and time to progression as end points of drug efficacy. Cancer J 2009;15:395–400.
Park JS, Lee YW, Cho JH, Son CG, Cho CK, Yoo HS. A case regression of advanced gastric cancer by herbal medicine a retrospective case study with 8-year follow-up. Kor J Orient Int Med 2007;28:193–198.
0
Views
647
Downloads
8
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
